The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Open accessAbstract
BACKGROUND: Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia. METHODS: In a 28-week randomized, controlled trial, we assessed the effects of benralizumab (at a dose of 30 mg administered subcutaneously either every 4 weeks or every 8 weeks [with the first three doses administered every 4 weeks]) versus placebo on the reduction in the oral glucocorticoid dose while asthma control was maintained in adult patients with severe asthma. The primary end point was the percentage change in the oral glucocorticoid dose from baseline to week 28. Annual asthma exacerbation rates, lung function, symptoms, and safety were assessed. RESULTS: ), as compared with placebo. The effects on various measures of asthma symptoms were mixed, with some showing significant changes in favor of benralizumab and others not showing significant changes. Frequencies of adverse events were similar between each benralizumab group and the placebo group. CONCLUSIONS: . (Funded by AstraZeneca; ZONDA ClinicalTrials.gov number, NCT02075255 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationOral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661
Self-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
Self-citationJuniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Moore, W. C., Bleecker, E. R., Curran-Everett, D., Erzurum, S. C., Ameredes, B. T., Bacharier, L., Calhoun, W. J., Castro, M., Chung, K. F., Clark, M. P., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.11.639 · Cited by 929
Self-citationBlood eosinophil count and prospective annual asthma disease burden: a UK cohort study
Price, D. B., Rigazio, A., Campbell, J. D., Bleecker, E. R., Corrigan, C. J., Thomas, M., Wenzel, S. E., Wilson, A. M., Small, M. B., Gopalan, G., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00367-7 · Cited by 591
Self-citationKolbeck, R., Kozhich, A., Koike, M., Peng, L., Andersson, C. K., Damschroder, M. M., Reed, J. L., Woods, R., Dall'Acqua, W. W., Stephens, G. L., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.004 · Cited by 586
Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort
Shaw, D. E., Sousa, A. R., Fowler, S. J., Fleming, L. J., Roberts, G., Corfield, J., Pandis, I., Bansal, A. T., Bel, E. H., Auffray, C., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.00779-2015 · Cited by 555
IL-5- and eosinophil-mediated inflammation: from discovery to therapy
Kouro, T., & Takatsu, K. (2009) · International Immunology · doi:10.1093/intimm/dxp102 · Cited by 422
Cited by
Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
Lambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
Biologic Therapies for Severe Asthma
Brusselle, G. G., & Koppelman, G. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032506 · Cited by 715
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Holguin, F., Cardet, J. C., Chung, K. F., Diver, S., Ferreira, D. S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., Knight, S., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00588-2019 · Cited by 629
GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation
Dougan, M., Dranoff, G., & Dougan, S. K. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.022 · Cited by 458
Metadata
- Authors
- Nair, P., Wenzel, S., Rabe, K. F., Bourdin, A., Lugogo, N. L., Kuna, P., Barker, P., Sproule, S., Ponnarambil, S., & Goldman, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-06-22
- Volume
- 376
- Issue
- 25
- Pages
- 2448-2458
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2619633721
- Cited by
- 1,044
- References
- 17
- FWCI
- 70.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma. https://app.cochat.ai/papers/10.1056/nejmoa1703501
- The paper
- Nair, P., Wenzel, S., Rabe, K. F., Bourdin, A., Lugogo, N. L., Kuna, P., Barker, P., Sproule, S., Ponnarambil, S., & Goldman, M. (2017). Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1703501
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.